. "Appendix C: Template for Submissions of Topics to the Agency for Healthcare Research and Quality." Knowing What Works in Health Care: A Roadmap for the Nation. Washington, DC: The National Academies Press, 2008.
The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
Knowing what Works in Health Care: A Roadmap for the Nation
Plans for Translation of the EvidenceReport into Derivative Products
EPCs take approximately one year to produce evidence reports/technology assessments. Organizations that nominate topics are responsible for translating the evidence reports and/or technology assessments into products that are useful for their memberships or other target groups. Please describe your plans for translating the evidence reports into quality improvement tools (e.g., clinical practice guidelines, performance measures), educational programs and/or coverage or reimbursement policies.
Plans for Dissemination of These DerivativeProducts to its Membership
Organizations nominating topics are responsible for disseminating the derivative products to their memberships or other target groups, as appropriate. Please describe your organization’s plans for disseminating these quality improvement tools (e.g., clinical practice guidelines, performance measures), educational programs, etc. Please include a description of the target groups of these products (e.g., organizational members, health professionals, patient/consumer groups, regulators, etc.), proposed dissemination media (e.g., journal articles, print media, Internet), and timeframe for dissemination.
How Organization will Measure Use of theProducts and Impact of Such Use
Organizations nominating topics are responsible for measuring the use of the derivative products and their impact. Please describe the process by which your organization will measure the use of the products and the impact of such use on clinical care. In addition, briefly describe any barriers to use or implementation of the derivative products (e.g., lack of funding, lack of patient compliance, professional resistance) and possible means to overcome these barriers (e.g., continuing education, changes in payment policies).